10-43109013-T-C
Variant names: 
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_020975.6(RET):c.1064-18T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000276 in 1,610,196 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
 Genomes: 𝑓 0.00016   (  0   hom.,  cov: 33) 
 Exomes 𝑓:  0.00029   (  4   hom.  ) 
Consequence
 RET
NM_020975.6 intron
NM_020975.6 intron
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  -0.394  
Publications
0 publications found 
Genes affected
 RET  (HGNC:9967):  (ret proto-oncogene) This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis. [provided by RefSeq, Sep 2017] 
RET Gene-Disease associations (from GenCC):
- familial medullary thyroid carcinomaInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, G2P
 - multiple endocrine neoplasia type 2AInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen, G2P
 - multiple endocrine neoplasia type 2BInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), ClinGen
 - pheochromocytomaInheritance: AD Classification: DEFINITIVE Submitted by: G2P
 - Hirschsprung disease, susceptibility to, 1Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
 - Haddad syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - Hirschsprung diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - renal agenesis, unilateralInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - bilateral renal agenesisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
 - renal agenesisInheritance: AR Classification: LIMITED Submitted by: G2P
 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88). 
BP6
Variant 10-43109013-T-C is Benign according to our data. Variant chr10-43109013-T-C is described in ClinVar as Benign. ClinVar VariationId is 560859.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. 
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.000164 (25/152316) while in subpopulation SAS AF = 0.00497 (24/4828). AF 95% confidence interval is 0.00343. There are 0 homozygotes in GnomAd4. There are 20 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check. 
BS2
High Homozygotes in GnomAdExome4 at 4 AD,AR gene
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| RET | NM_020975.6  | c.1064-18T>C | intron_variant | Intron 5 of 19 | ENST00000355710.8 | NP_066124.1 | 
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.000158  AC: 24AN: 152198Hom.:  0  Cov.: 33 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
24
AN: 
152198
Hom.: 
Cov.: 
33
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.000551  AC: 136AN: 246814 AF XY:  0.000725   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
136
AN: 
246814
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.000287  AC: 419AN: 1457880Hom.:  4  Cov.: 32 AF XY:  0.000396  AC XY: 287AN XY: 725416 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
419
AN: 
1457880
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
287
AN XY: 
725416
show subpopulations 
African (AFR) 
 AF: 
AC: 
2
AN: 
33460
American (AMR) 
 AF: 
AC: 
1
AN: 
44720
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
26134
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
39696
South Asian (SAS) 
 AF: 
AC: 
390
AN: 
86240
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
49838
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
5754
European-Non Finnish (NFE) 
 AF: 
AC: 
9
AN: 
1111686
Other (OTH) 
 AF: 
AC: 
17
AN: 
60352
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.478 
Heterozygous variant carriers
 0 
 32 
 63 
 95 
 126 
 158 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Variant carriers
 0 
 10 
 20 
 30 
 40 
 50 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome   AF:  0.000164  AC: 25AN: 152316Hom.:  0  Cov.: 33 AF XY:  0.000269  AC XY: 20AN XY: 74484 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
25
AN: 
152316
Hom.: 
Cov.: 
33
 AF XY: 
AC XY: 
20
AN XY: 
74484
show subpopulations 
African (AFR) 
 AF: 
AC: 
1
AN: 
41566
American (AMR) 
 AF: 
AC: 
0
AN: 
15302
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
3472
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
5186
South Asian (SAS) 
 AF: 
AC: 
24
AN: 
4828
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
10624
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
0
AN: 
68016
Other (OTH) 
 AF: 
AC: 
0
AN: 
2116
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.479 
Heterozygous variant carriers
 0 
 1 
 3 
 4 
 6 
 7 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
5
AN: 
3478
ClinVar
Significance: Benign 
Submissions summary: Benign:3 
Revision: criteria provided, multiple submitters, no conflicts
LINK: link 
Submissions by phenotype
not specified    Benign:1 
Dec 15, 2016
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Multiple endocrine neoplasia, type 2    Benign:1 
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not provided    Benign:1 
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.